Intellectual Property Licensing
•217 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (217)
| Company | Market Cap | Price |
|---|---|---|
|
DIS
The Walt Disney Company
Disney monetizes its extensive IP portfolio via Intellectual Property Licensing agreements.
|
$200.65B |
$110.95
-0.58%
|
|
QCOM
QUALCOMM Incorporated
Intellectual Property Licensing accurately reflects QTL's long-term, high-margin IP licensing revenue model.
|
$192.37B |
$177.46
-0.47%
|
|
ARM
Arm Holdings plc American Depositary Shares
Arm's primary revenue is intellectual property licensing for chip designs.
|
$137.96B |
$126.55
-3.32%
|
|
SNPS
Synopsys, Inc.
The company licenses intellectual property (design IP) as a core revenue stream.
|
$70.28B |
$462.20
+2.04%
|
|
TTWO
Take-Two Interactive Software, Inc.
Intellectual property licensing of TTWO's game IP/assets to partners is a distinct license-based revenue stream.
|
$44.54B |
$244.60
+1.30%
|
|
TKO
TKO Group Holdings, Inc.
Intellectual property licensing as a broader category for IP monetization.
|
$41.33B |
$205.35
-1.47%
|
|
ERIC
Telefonaktiebolaget LM Ericsson (publ)
Intellectual Property Licensing represents a key monetization channel via IPR licensing of Ericsson's technology.
|
$32.00B |
$9.57
|
|
FSLR
First Solar, Inc.
Licensing and enforcement of intellectual property (TOPCon patent portfolio) with licensing revenue.
|
$27.33B |
$252.99
-0.71%
|
|
CRDO
Credo Technology Group Holding Ltd
The company also participates in IP licensing revenue, which maps to Intellectual Property Licensing.
|
$24.90B |
$144.93
+0.71%
|
|
RPRX
Royalty Pharma plc
Royalties arise from intellectual property licensing of biopharma assets.
|
$22.39B |
$38.25
-0.36%
|
|
GFS
GLOBALFOUNDRIES Inc.
GF's acquisition of MIPS adds IP licensing revenue through RISC-V processor IP and related software tools.
|
$21.40B |
$37.78
-2.45%
|
|
XPEV
XPeng Inc.
Intellectual Property Licensing — IP licensing revenue from collaborations with Volkswagen.
|
$17.98B |
$18.68
-1.63%
|
|
GWRE
Guidewire Software, Inc.
Intellectual Property Licensing as Guidewire licenses software/IP to customers.
|
$17.34B |
$198.77
-3.09%
|
|
ROIV
Roivant Sciences Ltd.
Genevant's LNP/IP licensing revenue supports Intellectual Property Licensing.
|
$15.09B |
$21.93
-0.75%
|
|
NWS
News Corporation
Intellectual property licensing of IP assets to partners in AI/content domains.
|
$14.81B |
$29.55
-0.35%
|
|
WMG
Warner Music Group Corp.
WMG engages in intellectual property licensing related to its music catalogs and IP assets.
|
$14.49B |
$27.75
-0.16%
|
|
LYB
LyondellBasell Industries N.V.
LYB licenses polyolefin process technologies and sells catalysts, constituting intellectual property licensing activity.
|
$14.28B |
$42.41
-4.46%
|
|
HAS
Hasbro, Inc.
Hasbro monetizes intellectual property through licensing arrangements across media, entertainment, and consumer products.
|
$11.44B |
$81.58
+0.04%
|
|
RMBS
Rambus Inc.
Derives revenue from Intellectual Property Licensing, including silicon IP cores (HBM4 IP, PCIe 7 IP).
|
$10.14B |
$94.75
+0.55%
|
|
SARO
StandardAero, Inc.
Licensing of engine platform IP (CF34) and related technology.
|
$9.30B |
$27.24
-2.01%
|
|
IDCC
InterDigital, Inc.
InterDigital's core business is licensing its large patent portfolio (wireless, video, and AI technologies) to device makers and other partners, i.e., an Intellectual Property Licensing business.
|
$9.14B |
$352.49
-0.51%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme licenses its MDASE technology and related hyaluronidase IP (i.e., IP Licensing) to partners.
|
$7.28B |
$62.65
+0.71%
|
|
QS
QuantumScape Corporation
QuantumScape monetizes its development through Intellectual Property Licensing, including licensing agreements and royalty arrangements with automotive partners.
|
$6.68B |
$11.11
-5.85%
|
|
DLB
Dolby Laboratories, Inc.
Dolby's core revenue is through licensing its intellectual property and patents (e.g., Atmos, Vision), which fits Intellectual Property Licensing.
|
$6.47B |
$66.78
-1.13%
|
|
MNSO
MINISO Group Holding Limited
MINISO emphasizes developing proprietary IP and licensing IP across markets, a key driver of growth.
|
$6.07B |
$20.05
+2.58%
|
|
COGT
Cogent Biosciences, Inc.
Cogent engages in Intellectual Property Licensing via a license arrangement with Plexxikon for bezuclastinib, constituting Intellectual Property Licensing.
|
$5.88B |
$40.36
-4.16%
|
|
OLED
Universal Display Corporation
Licensing revenue is a core business model, via Intellectual Property Licensing.
|
$5.62B |
$119.29
+0.94%
|
|
KBR
KBR, Inc.
KBR licenses proprietary process technologies (ammonia, plastics recycling, lithium extraction) to customers.
|
$5.60B |
$42.92
-1.29%
|
|
ALKS
Alkermes plc
Intellectual property licensing and royalty arrangements with Janssen Biotech and Biogen.
|
$4.70B |
$28.03
-1.65%
|
|
VICR
Vicor Corporation
Vicor actively licenses IP and has realized licensing settlements, a material revenue stream.
|
$4.39B |
$97.16
-0.66%
|
|
PI
Impinj, Inc.
NXP patent settlement licenses IP revenue; licensing is a direct revenue stream.
|
$4.23B |
$148.69
+2.31%
|
|
LCID
Lucid Group, Inc.
Intellectual Property Licensing; licensing Lucid's tech to Aston Martin and other OEM discussions.
|
$4.17B |
$13.58
+5.43%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Ligand monetizes its proprietary technologies and licenses IP to pharma/biotech partners, generating royalty streams.
|
$3.71B |
$192.33
+1.47%
|
|
KFY
Korn Ferry
Licensing of Korn Ferry's IP and proprietary intelligence/data assets.
|
$3.66B |
$69.69
-0.27%
|
|
CNTA
Centessa Pharmaceuticals plc
Exclusive license agreement for LockBody with Genmab constitutes intellectual property licensing activity.
|
$3.55B |
$26.13
-1.43%
|
|
FOLD
Amicus Therapeutics, Inc.
The company engages in licensing and IP-focused transactions (e.g., DMX-200 license and IP protections for Galafold), mapping to Intellectual Property Licensing.
|
$3.25B |
$10.76
+1.94%
|
|
BEAM
Beam Therapeutics Inc.
Beam licenses complementary gene editing technologies (e.g., prime editing, Cas12b, RNA base editing), constituting an Intellectual Property Licensing activity.
|
$2.77B |
$27.23
-0.48%
|
|
IPAR
Inter Parfums, Inc.
Interparfums licenses intellectual property/assets (brands/fragrances) to third parties as a core revenue stream.
|
$2.70B |
$82.94
-1.50%
|
|
BB
BlackBerry Limited
BB licenses its intellectual property and AI/ML patents via the Licensing division, representing an IP licensing revenue stream.
|
$2.54B |
$4.31
+0.70%
|
|
CLVT
Clarivate Plc
Derwent IP data and related platforms involve Intellectual Property Licensing to customers.
|
$2.44B |
$3.50
+2.19%
|
|
LION
Lionsgate Studios Corp.
Lionsgate licenses its intellectual property and related assets to third parties, contributing to its revenue through IP licensing.
|
$2.37B |
$8.15
-0.49%
|
|
MESO
Mesoblast Limited
Intellectual property licensing and royalty income from collaborations (e.g., JCR, Takeda).
|
$2.08B |
$17.80
-1.52%
|
|
PRKS
United Parks & Resorts Inc.
Engages in IP/licensing arrangements around its park brands and content, aligning with Intellectual Property Licensing.
|
$2.02B |
$35.02
-4.42%
|
|
TGI
Triumph Group, Inc.
Triumph leverages proprietary IP in its aftermarket and platform-specific components, aligning with IP Licensing themes.
|
$2.01B |
$26.01
|
|
ZBIO
Zenas BioPharma, Inc.
Company engages in IP licensing and collaboration revenue with multiple partners.
|
$1.71B |
$34.87
-14.09%
|
|
WBTN
WEBTOON Entertainment Inc. Common stock
Licensing of intellectual property/assets to partners (e.g., Disney/Marvel/Star Wars) for broader media expansion.
|
$1.63B |
$12.62
+1.12%
|
|
WLYB
John Wiley & Sons, Inc.
Intellectual Property Licensing: licensing of IP/content to partners and AI/data licensing arrangements.
|
$1.61B |
$30.80
+0.59%
|
|
PCT
PureCycle Technologies, Inc.
PureCycle licenses the dissolution purification technology from Procter & Gamble, constituting a core IP licensing facet of the business.
|
$1.58B |
$8.43
-4.04%
|
|
WINA
Winmark Corporation
Brand IP licensing of the resale brands aligns with intellectual property licensing.
|
$1.58B |
$444.57
+0.01%
|
|
ADEA
Adeia Inc.
Adeia's primary business model is Intellectual Property Licensing, licensing a large portfolio of patents and IP assets.
|
$1.43B |
$12.88
-1.72%
|
|
RLAY
Relay Therapeutics, Inc.
Relay pursues intellectual property licensing and asset licensing (e.g., lirafugratinib licensing) as a business activity.
|
$1.38B |
$8.18
+1.81%
|
|
FBYD
Falcon's Beyond Global, Inc. Class A Common Stock
Intellectual property licensing supports cross-channel monetization of IP assets.
|
$1.36B |
$12.65
+12.44%
|
|
ANAB
AnaptysBio, Inc.
Revenues include licensing and monetization of royalties related to external assets (IP licensing).
|
$1.26B |
$44.45
-1.10%
|
|
XNCR
Xencor, Inc.
Business relies on licensing XmAb technology to partners with royalty/milestone monetization.
|
$1.18B |
$16.57
+0.33%
|
|
INBX
Inhibrx Biosciences, Inc.
License/IP assets licensing with third parties (Scithera) for non-dilutive funding potential.
|
$1.15B |
$78.44
-1.42%
|
|
NVAX
Novavax, Inc.
Novavax monetizes its intellectual property through licensing and milestone/royalty arrangements with partners (e.g., Sanofi).
|
$1.07B |
$6.54
-0.53%
|
|
RDW
Redwire Corporation
Space-derived intellectual property and licensing (e.g., crystal forms) align with 'Intellectual Property Licensing'.
|
$1.05B |
$6.92
-5.01%
|
|
MNMD
Mind Medicine (MindMed) Inc.
Exclusive licensing of Catalent's Zydis ODT technology represents Intellectual Property Licensing.
|
$954.90M |
$12.22
-2.63%
|
|
ABUS
Arbutus Biopharma Corporation
The company licenses its LNP technology and pursues IP litigation, making Intellectual Property Licensing a direct business line.
|
$902.90M |
$4.83
+2.65%
|
|
SLDP
Solid Power, Inc.
SLDP licenses its electrolyte technology and related cell manufacturing know-how to partners, fitting Intellectual Property Licensing.
|
$890.11M |
$4.75
-3.16%
|
|
SKYT
SkyWater Technology, Inc.
Intellectual property licensing could be a revenue stream tied to IP co-development with customers.
|
$866.20M |
$18.20
-1.52%
|
|
NRGV
Energy Vault Holdings, Inc.
Exclusive IP licensing revenue (B-Vault IP) fits Intellectual Property Licensing.
|
$796.33M |
$4.87
-1.02%
|
|
SCHL
Scholastic Corporation
Intellectual property licensing of core franchises and characters beyond publishing.
|
$725.69M |
$29.00
+0.12%
|
|
AIP
Arteris, Inc.
Arteris licenses NoC interconnect IP to semiconductor designers, making IP licensing a core revenue source.
|
$694.77M |
$16.04
-1.57%
|
|
PHCI
Panamera Holdings Corporation
PHCI's binding LOI/license for Rain Cage's carbon conversion technology constitutes intellectual property licensing.
|
$662.97M |
$8.30
|
|
RAPT
RAPT Therapeutics, Inc.
RPT904 licensing and exclusive rights indicate Intellectual Property Licensing activity.
|
$608.59M |
$34.69
-5.75%
|
|
NPWR
NET Power Inc.
Net Power's business model centers on licensing its Net Power Cycle IP to partners for commercial deployment.
|
$567.79M |
$2.54
-2.12%
|
|
HCKT
The Hackett Group, Inc.
Intellectual Property Licensing – licensing of Gen AI platforms/IP to clients and partners via the JV and related engagements.
|
$549.66M |
$19.73
-1.25%
|
|
CRNC
Cerence Inc.
Cerence licenses its AI/IP assets to customers and partners, aligning with intellectual property licensing themes.
|
$547.56M |
$13.06
+0.85%
|
|
LWLG
Lightwave Logic, Inc.
LWLG derives revenue from licensing its electro-optic polymer technology and providing technology transfers.
|
$537.18M |
$3.85
-7.11%
|
|
CEVA
CEVA, Inc.
CEVA's core business is IP licensing for DSPs, NPUs and wireless IP, making Intellectual Property Licensing a primary revenue source.
|
$521.35M |
$21.30
-2.45%
|
|
LENZ
LENZ Therapeutics, Inc.
LENZ engages in intellectual property licensing with international deals (Greater China, Southeast Asia, Canada), forming a core IP licensing revenue and moat.
|
$517.39M |
$17.30
-4.63%
|
|
RSVR
Reservoir Media, Inc.
Intellectual property licensing captures the broader IP licensing activity around music catalogs and related assets.
|
$498.90M |
$7.59
-0.20%
|
|
ADCT
ADC Therapeutics S.A.
The company derives license revenues and royalties from partnerships, fitting Intellectual Property Licensing.
|
$475.87M |
$4.13
-2.36%
|
|
ZVRA
Zevra Therapeutics, Inc.
Zevra engages in licensing of IP and out-licensing of pre-clinical assets; fits Intellectual Property Licensing.
|
$467.61M |
$8.26
-0.90%
|
|
SIGA
SIGA Technologies, Inc.
SIGA licenses intellectual property (monoclonal antibodies) to advance its pipeline, fitting Intellectual Property Licensing.
|
$462.57M |
$6.36
-1.63%
|
|
PRTC
PureTech Health plc
Portfolio royalties and milestones from KarXT/Cobenfy fall under Intellectual Property Licensing.
|
$436.16M |
$16.78
-0.77%
|
|
AMCX
AMC Networks Inc.
Licenses intellectual property across platforms, including IP libraries and franchises.
|
$434.27M |
$9.87
-1.40%
|
|
BYRN
Byrna Technologies Inc.
LATAM divestiture into licensing/distribution suggests material IP licensing revenue.
|
$425.02M |
$18.27
-2.38%
|
|
GRVY
Gravity Co., Ltd.
Ragnarok IP licensing is a core monetization channel, enabling merchandise and cross-media licensing.
|
$401.37M |
$56.09
-2.88%
|
|
ACTG
Acacia Research Corporation
Company monetizes patented portfolios via licensing and enforcement, core IP licensing business.
|
$371.31M |
$3.85
|
|
VALU
Value Line, Inc.
Intellectual property licensing related to Value Line's proprietary research technology and rankings.
|
$357.94M |
$38.04
|
|
CLLS
Cellectis S.A.
Cellectis licenses TALEN IP and related technologies (e.g., to Iovance), reflecting an IP licensing revenue/strategy.
|
$337.40M |
$4.79
+2.35%
|
|
ENTA
Enanta Pharmaceuticals, Inc.
The company monetizes IP via licensing/royalties (e.g., MAVYRET royalties and related licensing actions), aligning with Intellectual Property Licensing.
|
$314.90M |
$14.69
-0.27%
|
|
ZH
Zhihu Inc.
Intellectual property licensing for branded content and AI/IP assets.
|
$313.97M |
$3.29
-3.09%
|
|
XPER
Xperi Inc.
Intellectual Property Licensing is a core revenue and strategic lever for Xperi through its technology IP.
|
$284.96M |
$6.07
-1.54%
|
|
INV
Innventure, Inc.
Innventure licenses technologies and IP from MNCs, making Intellectual Property Licensing a core business activity.
|
$277.96M |
$5.38
-4.10%
|
|
QSG
QuantaSing Group Ltd
The company develops IPs and monetizes them through licensing arrangements, including exclusive and nonexclusive IP licenses.
|
$275.93M |
$5.81
+12.82%
|
|
OABI
OmniAb, Inc.
OmniAb's business model centers on licensing its Biological Intelligence platforms and IP to partners, supported by milestone and royalty economics.
|
$263.81M |
$2.10
-2.56%
|
|
SKYX
SKYX Platforms Corp.
Intellectual property licensing for SKYX's plug-and-play technology (licensing revenue).
|
$241.84M |
$2.23
+3.00%
|
|
EDIT
Editas Medicine, Inc.
Intellectual Property Licensing: monetization of IP through licensing deals with Vertex and DRI.
|
$227.50M |
$2.44
-3.56%
|
|
MRAM
Everspin Technologies, Inc.
Revenue from licensing IP and IP monetization, a material revenue stream for the company.
|
$207.25M |
$9.14
-0.22%
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
Strategic review emphasizes licensing IP/assets and monetizing IP, fitting Intellectual Property Licensing.
|
$206.13M |
$4.47
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet engages in licensing of its denifanstat IP with Ascletis for China, indicating an IP licensing business activity.
|
$202.61M |
$5.83
-6.34%
|
|
DERM
Journey Medical Corporation
Journey Medical monetizes its intellectual property via licensing/out-licensing deals (e.g., Emrosi and other assets).
|
$186.98M |
$7.67
|
|
PLBY
Playboy, Inc.
Intellectual property licensing of Playboy assets to partners/licensees is a direct business line.
|
$186.41M |
$1.84
-6.12%
|
|
SRM
SRM Entertainment, Inc.
SRM engages in IP licensing/transfer of IP assets to create products, aligning with Intellectual Property Licensing.
|
$177.61M |
$10.30
|
|
FCCN
Spectral Capital Corporation
Revenue from IP monetization through licensing is a direct business line.
|
$165.77M |
$2.15
|
|
BDTX
Black Diamond Therapeutics, Inc.
Licensing of BDTX-4933 to Servier constitutes Intellectual Property Licensing activity.
|
$158.85M |
$2.75
-1.61%
|
|
SAVA
Cassava Sciences, Inc.
Exclusive license agreement with Yale University — IP Licensing activity directly related to simufilam.
|
$154.10M |
$3.23
+1.10%
|
Showing page 1 of 3 (217 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
